Clinical trial

GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results

NCT05183243

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2022-02-20

PhasePHASE1

Study timeline

Study start (actual)2022-02-20Date precision: day

Registry last updated2024-07-16

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Advanced Solid Tumorunresolved

Non-Small Cell Lung Cancerunresolved

Pancreatic Cancerunresolved

Colorectal Cancerunresolved

Head and Neck Neoplasmunresolved

Interventions

GH21 CapsuleDRUG

Sponsors & collaborators

Suzhou Genhouse Bio Co., Ltd.lead sponsor

Mapped research locations

BeijingBeijing Municipality, China2 ZhengzhouHenan, China2 HangzhouZhejiang, China1 NanjingJiangsu, China1 ChongqingChongqing Municipality, China1 HefeiAnhui, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05183243 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.